Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Adelaide Research & Innovation Pty Ltd., part of University of Adelaide, is a company headquartered in Adelaide, Australia, that provides analytical research services. Robert Chalmers is the current CEO of the firm.

Axordia Ltd. develops human embryonic stem cell applications. Its applications include dry AMD, next generation stents, and GMP-compliant HESC lines. The company was founded by Peter W. Andrews and Harry Moore in 2001 and is headquartered in Sheffield, UK.

ImStem Biotechnology, Inc. operates as a biotechnology company. It focuses on developing cell therapeutic products. Its cell therapeutic products are derived from human pluripotent stem cells for tissue repair, treatment of neural, heart, vascular, blood system diseases and autoimmune diseases. The company was founded by Xinghua Victor Pan, Ren-He Xu, Michael Men, and Xiaofang Wang in June 2012 and is headquartered in Farmington, CT.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Provides research and development on medical sciences and pharmacy

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

The China-Japan Friendship Hospital (Chinese: 中日友好医院) was established through the cooperation of the Chinese and Japanese governments during the 1980s. The hospital has been directly affiliated with China's Ministry of Health since its first day of operation, October 23, 1984. The hospital is located on East Yinghuayuan Street, Chaoyang District, Beijing. The hospital covers 9.7 hectares, with floorspace of facilities measuring 180,000 square meters. Within the hospital, there are 1,500 beds, 58 departments, as well as a clinical research and education center. The hospital has intensive care and treatment of severe diseases as a primary focus and integrative eastern-western medicinal therapy as an additional area of expertise. The hospital often attends to the health care of senior officials from over 100 countries and regions.

GeneQuantum Healthcare (Suzhou) Co. Ltd. is a company headquartered in Suzhou, China, that engages in the research and development of biotherapeutics. The firm was founded in 2013 by Gang Qin, he has been the CEO since the company founding.\nThe company says this about itself: GeneQuantum is a global innovative biopharmaceutical company and one of the pioneers dedicated to the development of ADC drugs using enzyme-mediated site-specific conjugation technology. It has established a comprehensive technical system, iLDC® and iGDC®, which can provide end-to-end solutions for various conjugated drugs, from molecular design to commercial production. Based on this technology platform, GeneQuantum has successfully developed multiple clinically advanced innovative ADC products. ADC drugs empowered by GeneQuantum's conjugation technology have significant advantages in process quality and metabolic stability, with seamlessly integrated intelligent conjugation processes into antibody processes, resulting in a substantial reduction in overall commercial production costs. GeneQuantum is committed to empowering the development of various biopharmaceutical conjugated drugs worldwide and achieving collaborative partnerships and win-win cooperation in the field.

Aprogenex, Inc. manufactures surgical, medical and dental instruments and supplies. The company is headquartered in Houston, TX.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.

Zhuhai Hengqin Amstein Biotechnology Co., Ltd., established on 2014-12-11, The business scope includes the business scope recorded in the articles of association:Technology development, research and sales of stem cell engineering series products;R&D, production and sales of stem cell-related products;stem cell therapy.Monoclonal antibody diagnosis and treatment technology research,Develop application;Research and development of genetic diagnosis and treatment technology,application.Development and industrialization of new immunotherapy drugs,application;Biological product,Import and export of medical equipment;Technical Services,technology transfer,technical consulting,technology licensing.Research and development of other high-tech biotechnology,application.(The above business scope involves the certificate of industry license,Operate within the validity period,If the state has special franchise regulations, it shall be implemented in accordance with the regulations.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Oxford University Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Oxford University Innovation also manages Oxford University Consulting, which arranges consulting services providing clients access to the expertise of the University's academics. Oxford University’s overarching Strategic Plan begins, “The University of Oxford aims to lead the world in research and education” immediately followed by, “They seek to do this in ways which benefit society on a national and a global scale.” Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Their role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. They support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations.

Dalian Jinma Health Industry Development Co., Ltd., established on 2017-07-31, Business scope includes health industry development;Pension Industry Development;Research and development of biological products;biotechnology development,technical consulting,Technical Services,technology transfer;R&D and wholesale of medical devices;Home Care Services;Exhibition display service;Domestic general trade.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

BiOneCure Therapeutics, Inc. is an American private company located in Germantown, MD, that develops medicines for the treatment of cancer and enhancing cancer patients lives. It was founded by Yi Ning Zhao.\nThe company says this about itself: BiOneCure is an emerging biopharma dedicated to developing innovative ADC drugs for treatment of cancers. The company is led by industry veterans from Pfizer, AstraZeneca, Amgen, and other similar companies with successful drug discovery and development experience in ADC field. The company has developed proprietary payload platforms which enable a tailor-made approach for ADC drug development. The company is headquartered in Germantown, Maryland.